Table 3.
Multivariate analysis to identify variables that were associated with a greater probability of receiving opioid analgesics for a period longer than 12 months in a cohort of 1,129 patients with rheumatoid arthritis in Colombia.
| Variable | Beta | Siga | ORb | 95% CIc | |
|---|---|---|---|---|---|
| Lower | Upper | ||||
| Gender: female | −0.018 | 0.927 | 0.985 | 0.71 | 1.366 |
| Age <45 years | Ref | 0.004 | Ref | Ref | Ref |
| Age: 45–64.9 years | 0.585 | 0.014 | 1.782 | 1.127 | 2.819 |
| Age >65 years | 0.813 | 0.001 | 2.235 | 1.389 | 3.598 |
| Treated in Bogotá | −0.249 | 0.113 | 0.783 | 0.579 | 1.06 |
| Treated in Manizales | 0.734 | 0.01 | 2.067 | 1.187 | 3.596 |
| Acetaminophen | 0.189 | 0.24 | 1.202 | 0.884 | 1.634 |
| Use of antidepressants | 0.446 | 0.001 | 1.553 | 1.193 | 2.021 |
| Use of anticonvulsants | 1.192 | 0.001 | 3.163 | 1.606 | 6.230 |
| Use of benzodiazepines | 1.182 | 0.004 | 3.203 | 1.462 | 7.018 |
| Treated with biological DMARDs | 0.422 | 0.014 | 1.524 | 1.09 | 2.131 |
| Use of systemic corticosteroids | 0.474 | 0.01 | 1.61 | 1.121 | 2.313 |
aSignificance level. bOR: odds ratio. c95% confidence interval. DMARDs: disease modifying antirheumatic drugs.